Ohta Shoichiro, Fuse Hideki, Fujiuchi Yasuyoshi, Nagakawa Osamu, Furuya Yuzo
Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630, Sugitani, Toyama, Japan.
Anticancer Res. 2003 May-Jun;23(3C):2945-50.
Urokinase-type plasminogen activator (u-PA) has been reported to overexpress in several types of human cancers and correlate with cancer progression. The present study was performed to evaluate the significance of expression of u-PA on the progression of prostate cancer.
Expression of u-PA protein was investigated immunohistochemically on paraffin-embedded section from 61 patients with untreated prostate cancer. The correlation between the u-PA expression and clinical outcome was examined.
u-PA was expressed in the cytoplasm of glandular cells of 56% patients. Higher expression of u-PA protein was positively correlated with bone metastasis (p = 0.011). The cause-specific survival rate was significantly lower in u-PA-positive patients than that in u-PA-negative patients (p = 0.0012). In those with bone metastasis, patients with u-PA expression had worse cause-specific survival than those without u-PA expression (p = 0.030).
Increased expression of u-PA is a feature of bone metastasis in patients with prostate cancer. u-PA expression is a prognostic factor in patients with prostate cancer.
据报道，尿激酶型纤溶酶原激活剂（u-PA）在多种人类癌症中过度表达，并与癌症进展相关。本研究旨在评估u-PA表达在前列腺癌进展中的意义。
采用免疫组织化学方法检测61例未经治疗的前列腺癌患者石蜡包埋切片中u-PA蛋白的表达。检测u-PA表达与临床结局之间的相关性。
56%的患者腺细胞胞质中表达u-PA。u-PA蛋白的高表达与骨转移呈正相关（p = 0.011）。u-PA阳性患者的病因特异性生存率显著低于u-PA阴性患者（p = 0.0012）。在有骨转移的患者中，u-PA表达者的病因特异性生存率比无u-PA表达者更差（p = 0.030）。
u-PA表达增加是前列腺癌患者骨转移的一个特征。u-PA表达是前列腺癌患者的一个预后因素。
